Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | January 2005 |
| End Date: | December 2006 |
A Pilot Trial to Correlate Serum Levels of Calgranulin A and B With Estrogen Receptor Status Among Patients With Breast Cancer
RATIONALE: Measuring levels of calgranulin A and calgranulin B in the blood of patients with
breast cancer in the laboratory may help doctors identify and learn more about biomarkers
related to breast cancer.
PURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the
blood of patients with newly diagnosed stage I, stage II, or stage III breast cancer.
breast cancer in the laboratory may help doctors identify and learn more about biomarkers
related to breast cancer.
PURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the
blood of patients with newly diagnosed stage I, stage II, or stage III breast cancer.
OBJECTIVES:
- Determine circulating levels of calgranulin A and calgranulin B in patients with
estrogen receptor negative or estrogen receptor positive, newly diagnosed, primary
stage I-III adenocarcinoma of the breast.
OUTLINE: This is a pilot study.
Patients undergo a blood draw following diagnosis of breast cancer to assess levels of
circulating tumor markers, calgranulin A and calgranulin B. Serum samples are evaluated by
enzyme-linked immunosorbent assay for tumor marker expression.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
- Determine circulating levels of calgranulin A and calgranulin B in patients with
estrogen receptor negative or estrogen receptor positive, newly diagnosed, primary
stage I-III adenocarcinoma of the breast.
OUTLINE: This is a pilot study.
Patients undergo a blood draw following diagnosis of breast cancer to assess levels of
circulating tumor markers, calgranulin A and calgranulin B. Serum samples are evaluated by
enzyme-linked immunosorbent assay for tumor marker expression.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
DISEASE CHARACTERISTICS:
- Histologically confirmed primary adenocarcinoma of the breast
- Stage I-III disease
- No evidence of metastatic disease
- Newly diagnosed disease
- Hormone receptor status:
- Estrogen receptor-positive- or -negative tumor
PATIENT CHARACTERISTICS:
Sex
- Not specified
Menopausal status
- Not specified
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- Not pregnant
- No Crohn's disease
- No arthritis
- No psoriasis
- No lupus erythematosus
- No multiple sclerosis
- No other severe active inflammation
- Not C-reactive protein positive
- No HIV positivity
- No other serious medical or psychiatric illness
PRIOR CONCURRENT THERAPY:
Radiotherapy
- No prior radiotherapy for breast cancer
Surgery
- No prior organ transplantation
Other
- No prior systemic therapy for breast cancer
We found this trial at
1
site
Cleveland, Ohio 44106
Click here to add this to my saved trials
